Grant of Options and PDMR notification

RNS Number : 6510L

Oncimmune Holdings PLC

01 May 2020

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR notification

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening,  detection and care of cancer, today announces t hat options to subscribe for an aggregate 546,052 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted to Matthew Luttrell, Chief Commercial Officer, Tariq Sethi, Chief Scientific Officer, and Ron Kirschner, General Counsel & Company Secretary as follows:

Name	Position	Number of Share Options Awarded	Exercise Price per Share
Matthew Luttrell	Chief Commercial Officer	223,684	£0.76
Tariq Sethi	Chief Scientific Officer	92,105	£0.76
Ron Kirschner	General Counsel & Company Secretary	230,263	£0.76

The Options have been granted under the 2016 Share Option Plan and have an exercise price of £0.76, being the closing price of shares at 30 April 2020.  

Other than the grant of the Options, none of Mr Luttrell, Mr Sethi or Mr Kirschner or their respective connected persons have any beneficial interest in the Ordinary Shares of the Company.

This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1)  Matthew Luttrell 2)  Tariq Sethi 3)  Ron Kirschner
2	Reason for the notification
a)	Position/status	1)  Chief Commercial Officer 2)  Chief Scientific Officer 3)  General Counsel & Company Secretary
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BYQ94H38
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1) £0.76	223,684
			2) £0.76	92,105
			3) £0.76	230,263
d)	Aggregated information
	- Aggregated volume	546,052
	- Price	£414,999.52
e)	Date of the transaction	1 May 2020
f)	Place of the transaction	Outside a trading venue

For further information:

Oncimmune Holdings plc

Ron Kirschner, General Counsel & Company Secretary

[e-mail]

 

END

 

 

DSHUPUBPAUPUUBG